Genmab — Marts 2020
-
Morgan Stanley raises EPS estimates for Genmab Morgan Stanley analyst Matthew Harrison maintained an Overweight rating and $31 price target on Genmab and raised his EPS estimates for FY20 and FY21.
The Fly | LANDINGPAGENEWS.PHP
Real-time market news, financial data, stock research, and portfolio tools from The Fly.
(thefly.com)
-
-
Thanks E L
-
UST IN: The S&P 500 rallied 4.9% in the biggest surge since December 2018 https://trib.al/ekCbRze
-
God morgen.
-
-
Tak bibob:-)
-
-
i couldnt read the fiercebiotech, this is the JNJ press release
https://www.jnj.com/janssen-announces-u-s-fda-breakthrough-therapy-designation-granted-for-jnj-6372-for-the-treatment-of-non-small-cell-lung-cancer
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind